Speaker Program
Select a course or conference day to view presentation details. Program subject to change.
Post-Graduate Course
Thursday 1 April 2027
Post-Graduate Course
08:30–08:50
CURRENT HBV guidelines and Harmonisation of HBV terminology
George LAU
08:50–09:20
HDV Management in 2027
JESS HOWELL
09:20–09:40
HCV towards elimination (where are the untreated and how to treat incl non-medical models)
SAEED HAMID
09:40–10:00
Approach to DILI incl immunotherapy
Harshad Devabharvi (India)
10:30–10:50
MAFLD Models of care - low fibrosis to advanced fibrosis
Zoubair Younossi (US)
10:50–11:10
Update on MAFLD pharmacotherapy
WON KIM KOREA
11:10–11:25
HCC Global burden and diagnosis
Ericka Flores (Aust-ACT)
11:25–11:45
Treatment landscape for HCC (Curative and non-curative treatment options )
Michael Wallace (Aus-WA)
11:45–12:00
Treatment landscape HCC -systemic therapy iand palliative care
ROHINI SHARMA (UK)
13:00–13:20
Cirrhosis - diagnosis and risk stratification
Eugene Wong (Singapore)
13:20–13:40
TIPS - patient selection to management of complications
Paolo Caraceni (italy)
13:40–14:00
Renal impairment (incl a section on what isn't HRS) and HE
Florence Wong (Can)
14:00–14:20
PHT related respiratory disorders
Claire Ellender (Aust)
14:20–14:40
ACLF
Jasmohan Bajaj (US)
14:40–15:00
Optimising referrals for liver transplantation - who and how
Caroline Tallis (Aust)
15:30–15:50
Holistic care in ALD
Michael Lucey US
15:50–16:10
AIH
TBC
16:10–16:30
Key concepts in diagnosis and management of inherited disorders of the liver
Winita Hardikar
16:30–16:45
What's new in PSC
TBC
16:45–17:00
What's new in PBC
John Lubel (Aust-VIC)
Basic Science Course
Basic Science Course
Session times to be confirmed · Four 90-minute sessions
Session 1: Mapping the Tissue Architecture: Spatial & Single-Cell Staging of Liver Cancer Beyond BCLC
20 min
Oncofetal niches & tumour architecture
Prof. Ankur Sharma (Garvan, Australia)
20 min
Integrating spatial atlas in liver cancer from Japan
Prof. Yutaka Suzuki (University of Tokyo, Japan)
20 min
Single-cell dissection of HCC: molecular stratification beyond BCLC
Dr. Ziyi Li (China)
20 min
Single-cell analysis of HCC heterogeneity and clinical correlates
Prof. Takahiro Kodama (Osaka University, Japan)
10 min
Selected abstract (short talk)
TBC
Session 2: Building the Blueprint: From Genomes and Models to Precision Targets
20 min
HCC cancer genomics: mutational landscapes & actionable signatures
Prof. Hidewaki Nakagawa (RIKEN, Japan)
20 min
Cancer stem cells & tumour heterogeneity as therapeutic vulnerabilities
Prof. Stephanie Ma (HKU, Hong Kong)
20 min
Organoid and assembloid models of liver cancer
Dr. Rio Sugimura (HKU, Hong Kong)
20 min
In vivo and metabolic models to nominate therapeutic targets
Prof. Andrew Cox (Peter Mac, Australia)
10 min
Selected abstract (short talk)
TBC
Session 3: Arming the Immune Synapse: Cellular, Humoral & Vaccine Strategies for Liver Cancer
20 min
Engineered T cells / TCR-T for HBV-related HCC
Prof. Antonio Bertoletti (Duke-NUS, Singapore)
20 min
HBV biology and the immune interface
Prof. Yang Cheng (Academia Sinica, Taiwan)
20 min
mRNA / therapeutic vaccine strategies in liver cancer
Dr. Diyana Hassanel (Garvan, Australia)
20 min
Spatial immune profiling of the tumour microenvironment
Dr. Valerie Chew (Duke-NUS, Singapore)
10 min
Selected abstract (short talk)
TBC
Session 4: The Asia-Pacific Precision Oncology Consortium (ASTRA): Turning Regional Diversity into Scientific Strength
20 min
ASTRA: a regional spatial-translational alliance - vision & shared resource
Prof. Ankur Sharma (Garvan, Australia)
20 min
Japan-ASTRA: national spatial atlas initiatives in liver cancer
Prof. Yutaka Suzuki (University of Tokyo, Japan)
20 min
Korea-ASTRA: spatial genomics flagship programmes
Prof. Woong-Yang Park (Samsung Genome Institute, Korea)
20 min
India-ASTRA: spatial biology of liver cancer in a resource-diverse setting
Prof. S. Mahalingam (IIT-Madras, India)
10 min
Roundtable - turning regional diversity into an equitable shared data resource
ALL
Day 1
Friday 2 April 2027
Shifting the paradigm in Hepatitis B/D treatment
08:30–10:00 · Room 1
08:30–08:45
Hepatitis D – best practice in 2027
Seng Gee Lim (Singapore)
08:45–09:00
Bepirovirsen – will it be a game changer?
MF Yuen (HK)
09:00–09:15
New leads – novel mechanisms of action
Walter Seto (HK)
09:15–09:30
Sterilising cure – is it possible?
Jing Chen (HK)
09:30–09:45
Translating fantasy into reality-The path forward to implement new HBV cures
Jordan Feld
Staging Wars – BCLC Conservatism vs. Asian Borderline Resectable Paradigm
08:30–10:00 · Room 2
08:30–08:50
Asian Paradigm: Beyond BCLC – Borderline Resectable & Aggressive Conversion
TBC
08:50–09:10
Western View: BCLC 2025 – Why Conservatism Still Wins in Staging & Downstaging
Prof Stuart Roberts (Aust)
09:10–09:30
Radioembolization before the knife: redefining resectability in HCC beyond Milan
Prof Yoon Jun Kim
09:30–09:50
Neoadjuvant TKI + ICI: High Conversion Rates in Asian PVTT/Multifocal Cases
Prof. Shuqun Cheng, MD, PhD
Screening and Non-invasive testing in MAFLD
08:30–10:00 · Room 3
08:30–08:50
Is population screening for MAFLD fibrosis justified?
Christos Mantzoros (US)
08:50–09:10
Screening for fibrosis in MAFLD: Should we still be using FIB-4?
Ming-Lung YU (Taiwan)
09:10–09:30
Interpreting changes in NIT's over time: disease progression and treatment response
VINCENT WONG (HK)
09:40–09:50
Paper 1
TBC
09:50–10:00
Paper 2
TBC
Risk Stratification 2.0: From Baveno 8 to Precision Hemodynamics in the Asia-Pacific region
08:30–10:00 · Room 4
08:31–08:46
Advanced Chronic Liver Disease and Portal Hypertension in the Asia-Pacific context
Angus Jeffrey (Aust)
08:46–09:06
Baveno 8 in Practice
Emmanouil Tsochatzis (UK)
09:06–09:21
NITs that Matter: VCTE, Spleen Stiffness, blood based biomarkers, MRI Elastography
William Kemp (Aust)
09:21–09:31
EUS-portal pressure gradient – how does it help?
Bronte Holt (Aust)
09:31–09:46
Novel pharmacological targets for MASH and portal hypertension
TBC- guest speaker pharma
09:46–10:00
Debate: Is the concept of CSPH still relevant or can NITs independently be used to predict risk?
Emmanouil Tsochatzis (UK) & James O'Beirne
Welcome to the meeting
10:30–12:00 · Room 1
10:30–10:50
Welcome to country, MP welcome
TBC
APASL president and Meeting Chair welcomes
10:30–12:00 · Room 1
10:50–11:00
APASL President welcome, president elect?, Meeting Chair welcome
Jacob George, TBC
Presidential Lecture
10:30–12:00 · Room 1
11:00–11:15
Viral hepatitis
Professor Ed Gane
HBV Models of care – NA therapy
13:30–15:00 · Room 1
13:30–13:50
Debate: People living with immunotolerant hepatitis B should all be started on NA
Ben Cowie (Aust) vs Jordan Feld (Canada)
13:50–14:10
What do people want?
Thomas Tu and Su Wang
14:10–14:30
Applying guidelines in practice – how have the new Chinese guidelines for treating HBV changed practice?
Hong You (China)
14:30–14:50
HCC surveillance in 2027 – Japanese program and what can we learn.
Peipei SONG, M.P.H., Ph.D.
Emerging Biomarkers for IO Resistance & Personalization – Practical Tools in 2027
13:30–15:00 · Room 2
13:30–13:50
HCC Biopsy for Decision Making- The Australian experience
Prof. Michael Wallace, MBBS, PhD
13:50–14:10
Gut Microbiome as a Predictive Tool for Immunotherapy Response in HCC: Evidence & Potential Adjuncts
A/Prof. Amany Zekry, MD, FRACP, PhD
14:10–14:30
TME & Resistance Profiling in Advanced HCC: Insights from Tissue & Liquid Approaches
Dr. Sadahisa Ogasawara, MD
14:30–14:50
Biomarkers for Next-Gen Therapies in HCC: From Resistance to Personalization – Global Insights
Dr. Angela Lamarca, MD, PhD
Pathogenesis and clinical implications
13:30–15:00 · Room 3
13:30–13:50
Is MASH a mitochondrial disease?
Rotonya Car (US)
13:50–14:10
Monogenetic causes of hepatic steatosis: Are we missing them in the clinic?
Rohit Loomba (US)
14:10–14:30
Sub-types of MAFLD: Learnings from omics data
Mohammed Eslam (AUS)
14:30–14:50
The role of alcohol in MAFLD progression
Diana Payawal (phillipines)
APASL-EASL Special Session — ACLF/ PHT
13:30–15:00 · Room 4
13:30–13:50
Implementing the ACLD concept in clinical practice: diagnosis, risk stratification and challenges across different healthcare settings
Shiv Sarin
13:50–14:10
Prevention of first and further decompensation in ACLD- current standards and emerging strategies
Paolo caraceni
14:10–14:30
Microbiome interventions for decompensated ACLD- what's new?
Debbie Shawcross
14:30–14:50
Recompensation of ACLD: Mechanisms and clinical implications
Qin Ning
Cholestatic conditions – kids, adults and pregnancy
13:30–15:00 · Room 5
13:30–13:55
State of the Art: Current and future management of PBC
Cynthia Levy (US)
13:55–14:00
Paediatric PFIC case
Fellow Aust
14:00–14:15
Genetic cholestatic disorders – what’s new? Paediatric
Winita Hardika (NSW)
14:15–14:20
Adult BRIC/ ICP case
Fellow- Sanchit Sharma (Aust)
14:20–14:35
Obstetric cholestatic disorders – what’s new? Adult (incl case study)
Siyang Liu (China)
14:35–14:40
Patient lived experience (?PFIC ?PBC)
Patient TBC
Innovations in hepatitis C to advance elimination
15:30–17:00 · Room 1
15:30–15:45
The role of new direct-acting antiviral therapy regimens
Soek-Siam Tan (Malaysia)
15:45–16:00
Ultra-short course direct-acting antiviral therapy
Marianne Martinello (Australia)
16:00–16:15
Long-acting treatment for hepatitis C and other new treatments
Ju Hyun Shin (Korea)
16:15–16:30
Point-of-care hepatitis C screening
Jason Grebely (Australia)
Systemic + Locoregional Synergies – East-West Sequencing Clashes
15:30–17:00 · Room 2
15:30–15:50
Triple/Quad IO + TKI: Asia's Aggressive Frontline Evolution
Prof. Shukui Qin, MD, PhD
15:50–16:10
SIRT/TARE + IO Synergy: STRATUM & Dosimetry Edge
Prof. Pierce Chow, MBBS, PhD
16:10–16:30
STRIDE/HIMALAYA Update: Resistance & Post-First-Line in Asian Practice
Prof. Stephen Lam Chan, MD, FRCP
16:30–16:50
Sequencing Wars: Locoregional First vs. Systemic – Traps & Wins
Prof. Hiroshi Aikata, MD
MAFLD Management
15:30–17:00 · Room 3
15:30–15:45
Prescribing exercise medicine for MAFLD (both with and without GLP1s)
Shelley Keating (Australia)
15:45–16:00
Nutritional therapy for MAFLD: Is it all just weight loss?
Elena George (Australia)
16:00–16:20
Current pharmacotherapeutic options for MASH
Jorn Schattenberg (Germany)
16:20–16:40
Emerging pharmacotherapeutics and treatment strategies for MASH
Mazen Noureddin (USA)
16:40–17:00
Case presentation and panel Discussion
Panel / case presenter TBC
Variceal Bleeding Masterclass: From Door‑to‑Haemostasis to Secondary Prophylaxis
15:30–17:00 · Room 4
15:31–15:46
State of the Art: Acute variceal bleeding
Jacinta Holmes
15:46–16:01
New endoscopic techniques in variceal bleeding
Prarthana Thiagarajan
16:01–16:16
Pre‑Emptive TIPS: Who, When, How
Golo Ahlenstiel (Aust)
16:16–16:31
BRTO/CARTO & Ectopic Varices in APAC
Richard pow (Aust)
DILI session
15:30–17:00 · Room 5
15:30–15:40
Update of APASL DILI registry
Necati Ormeci (Turkey/ Bangalore)
15:40–15:50
Update of AUSDILIN registry
Amanda Nicoll (Aust)
15:50–16:10
DILI in the era of Immunotherapy and Targeted Oncology
James Haridy (Aust)
16:10–16:30
DILI from 'Unregulated' substances: Dietary and Herbal supplements and Traditional Medicines
Ajay Duseja (India)
16:30–16:50
Precision Medicine, Artificial Intelligence and Emerging Biomarkers for DILI
Dr Wasim Jafri (Pakistan)
Day 2
Saturday 3 April 2027
Biomarkers and natural history / new treatment endpoints
08:30–10:00 · Room 1
08:30–08:50
HBsAg levels - what does it mean?
Teera Pirasvituh (Thailand)
08:50–09:10
How to interpret liver stiffness in CHB
Grace Wong (HK)
09:10–09:30
Novel biomarkers - HBcrAg, HBV RNA, anti-HBc level - what's it all mean?
Mark Douglas (Australia)
09:30–09:50
Treating kids w CHB
Loey MAK (HK)
MAFLD and Hepatocellular Carcinoma
08:30–10:00 · Room 2
08:30–08:50
Is the epidemiology of MAFLD related HCC changing in the Asia-Pacific?
Daniel Huang (Singapore)
08:50–09:10
Risk stratification: Identifying which patients should undergo HCC surveillance
Tawesak Tanwandee (Thailand)
09:10–09:30
HCC surveillance strategies in patients with MAFLD: ultrasound or other?
Anand Kulkarni (india)
09:30–09:50
Optimizing treatment outcomes for MAFLD related HCC
Elizabeth Powell (Aust)
APASL AASLD Theme — ALD
08:30–10:00 · Room 3
08:30–08:50
What are the limits of alcohol consumption across stages in ALD?
Brian Lee (US)
08:50–09:10
Use of GLP1s across the spectrum
Maja Thiel (Denmark)
09:10–09:30
Biology of alcohol use in liver disease
Kenichi Ikejima (Japan)
09:30–09:50
how does alcohol fit into the liver transplant algorithm
Penny Hey (Aust) (TBC)
The evolving landscape of liver transplantation
08:30–10:00 · Room 4
08:30–08:50
Acute alcoholic hepatitis, the role of liver transplant for alcohol-related liver disease within the traditional 6 months of abstinence
Rakhi Maiwall (India)
08:50–09:10
Emerging prioritisation systems - GEMA, MELD 3.0, MELD-sarcopenia
Angus jeffrey (Aus)
09:10–09:30
Too fat/too frail/too old/too comorbid - how to manage our increasingly complex patient cohort
TBC
APASL-ALEH Special Session
10:30–12:00 · Room 1
10:30–10:50
Talk topic TBC
Nelia Hernandez (Uruguay)
10:50–11:10
Talk topic TBC
Mario Pessoa (Chile)
11:10–11:30
Talk topic TBC
George Lau (HK)
11:30–11:50
Talk topic TBC
Loey Mak (HK)
Curative Horizon – Neoadjuvant, SBRT/SABR & East-West Convergence
10:30–12:00 · Room 2
10:30–10:50
SOCRATES HCC: SBRT vs. Ablation – Australian Disruption of Early Curative Standards
Prof. Alan Wigg, MD
10:50–11:10
Neoadjuvant/Adjuvant IO: Western Trial Maturation & High-Risk Stratification
Prof Takahiro Kodama MD
11:10–11:30
Next-Gen IO: GPC3-CAR-T, Bispecifics & Resistance Reversal – Global Signals
Prof Lara Lipton (AUST)
11:30–11:50
Radiation Oncology in 2027 HCC: SBRT/SIRT + IO – East-West Integration for Curative Push
Prof Julie Chu (Australia)
Cirrhosis and transplant in the patient with MAFLD
10:30–12:00 · Room 3
10:30–10:50
Does diagnosing cACLD vs cirrhosis in MAFLD matter?
Ming-Hua Zheng (China)
10:50–11:10
Managing weight loss in patients with MAFLD related cirrhosis
Mark Muthiah (Singapore)
11:10–11:30
Pharmacotherapy for MAFLD cirrhosis: current and emerging strategies
Leon Adams (Australia)
11:30–11:50
Transplantation challenges in MAFLD: Obesity, sarcopenia and multi-morbidity
Debbie Shawcross (UK) Coming as EASL secretary General
Moving past endoscopic variceal ligation as the default — toward risk-stratified, EUS-driven, and shunt-based care.
10:30–12:00 · Room 4
10:30–10:45
Keynote: Bridging the Gap: Lumen to Liver
Manoj Kumar Sharma (India)
10:45–11:00
Rethinking Risk Stratification: From HVPG to EUS-Guided Portal Pressure Gradient (EUS-PPG)
Jason Huang
11:00–11:20
Gastric Varices Without a Needle in the Dark: EUS-Guided Coil and Glue Embolization
Cynthia Thilakanathan
11:20–11:35
WHO wins in 2027: BRTO, TIPS or EUS-IPS: Outcomes, Patient Selection, and When Each Wins
David Leggett
11:35–11:50
Pharmacotherapy Meets Endoscopy: Primary prophylaxis in 2027: Optimising NSBB, Combination Therapy, and When Banding Still Wins
Manoj Kumar Sharma (India)
HBV reactivation –an increasing phenomenon in a new era?
13:30–15:00 · Room 1
13:30–13:50
Immunosuppression - who needs prophylaxis?
Simone Strasser (Australia)
13:50–14:10
Preventing post-transplant HBV recurrence
James Fung (HK)
14:10–14:30
HIV-HBV coinfection
Gail Matthews (Australia)
14:30–14:50
CHB – when to stop NA?
Rachel Jeng (Taiwan)
Nurse session 1 — HCC
13:30–15:00 · Room 2
13:30–15:00
Individual talks to be confirmed
TBC
MAFLD: Diagnosis and Assessment
13:30–15:00 · Room 3
13:30–13:50
Emerging diagnostics for hepatic steatosis
Jian-Gao Fan (China)
13:50–14:10
Sarcopenia in MAFLD: Clinical significance and management
Seung Up Kim (Korea)
14:10–14:30
Alcohol intake in SLD: recognition and management
Takumi Kawaguchi (japan)
14:30–14:50
Identifying MASLD patients for pharmacotherapy
Atsushi Nakajima (Japan)
Longitudinal Management of Decompensation, ACLF and PSVD Special Populations
13:30–15:00 · Room 4
13:31–13:46
Ascites & Refractory Ascites: Albumin, Terlipressin, LVP and TIPS
Rakhi Maiwall
13:46–14:06
HE, Sarcopenia, and Nutrition
Marie Sinclair
14:06–14:26
Key Developments in ACLF: Beyond Kyoto
Anand Kulkarni
14:26–14:46
PSVD: new name but what has changed in APAC?
Premkumar Madhumita
FREE PAPERS 5 — Viral hepatitis
15:30–17:00 · Room 1
15:30–17:00
Individual free-paper abstracts / talks TBC
TBC
FREE PAPERS 6 — HCC / liver oncology
15:30–17:00 · Room 2
15:30–17:00
Individual free-paper abstracts / talks TBC
TBC
FREE PAPERS 7 — MAFLD / metabolic / ALD
15:30–17:00 · Room 3
15:30–17:00
Individual free-paper abstracts / talks TBC
TBC
FREE PAPERS 8 — Cirrhosis / PHT / transplant
15:30–17:00 · Room 4
15:30–17:00
Individual free-paper abstracts / talks TBC
TBC
APASL International Guidelines Launch Session
15:30–17:00 · Room 5
15:30–15:50
Harmonisation of HBV terminology- launch
Norah terrault (USA)
15:50–16:10
MCPF/ PSVD
Akashi Shukla (India)
16:10–16:30
APASL MAFLD
Harendran Elangovan (Aust)
16:30–16:50
APASL extrahepatic ACLF
Qin Ning (China)
Day 3
Sunday 4 April 2027
Session TBC
Room 6
08:30–08:45
Hep B PAST program for First Nations Australians
Jane Davies (Aust)
08:45–09:00
VH care in the Pacific
Alice Lee (Aust)
09:00–09:15
PBBK trial Vanuatu and Solomons
Caroline van Gemert (Aust/ Vanuatu)
09:15–09:30
TBC- NZ speaker OR Kathy Jackson HDV in Pacific
Kathy jackson or Chris Cunningham?
Impact of hepatitis C elimination on morbidity and mortality
08:30–10:00 · Room 1
08:30–08:45
Declines in hepatitis C related Cirrhosis & Liver Disease
Raoh-Fang (Jasmine) Pwu (Taiwan)
08:45–09:00
Impacts on Hepatocellular carcinoma
Heather Valerio (Australia)
09:00–09:15
Economic evaluation of HCV elimination at a national level
Nick Scott (Australia)
09:15–09:30
Beyond 2030 - what next? Lessons from Hepatitis C that can drive policy responses to steatotic liver disease
Jeffrey V Lazarus (Spain)
Transplant Oncology
08:30–10:00 · Room 2
08:30–08:50
HCC update - current HCC criteria, the role of downstaging and the use of immunotherapy pre-liver transplant
KEN Liu (Australia)
08:50–09:10
HCC and living donation transplantation - how this impacts the transplant landscape in Asia vs Australasia
Louise Barbier + Kwang Woong Lee (korea)
09:10–09:30
Novel cancer indications for transplant - cholangiocarcinoma, colorectal cancer metastases, rare cancers
Marcos Perini (Australia)
APASL Special Session: Community based screening Trial — CHESS
08:30–10:00 · Room 3
08:30–08:50
Prevalence of liver fibrosis and steatotic liver disease in community-dwelling adults in China (the LiverHealth project)
Xiaolong Qi (China)
08:50–09:10
Screening and Risk Stratification of MAFLD: From Detection to Personalized Management
Xinrong Zhang (China)
09:10–09:30
Screening for MAFLD at population Level: Learnings from Japan’s efforts in HCV case finding
TBC
09:30–09:50
Models for community-based MAFLD screening in Australia: What works in primary care
Elizabeth Powell (Aust)
APASL-ASCITES CLUB Special Session
08:30–10:00 · Room 4
08:30–08:50
TBC
Avik Majumdar (Aust)
08:50–09:10
TBC
Rakhi Maiwall (India)
09:10–09:30
TBC
TBC
09:30–09:50
TBC
TBC
Pushing Boundaries – PVTT Mastery: East-West Clashes & Convergence
10:30–12:00 · Room 2
10:30–10:50
Japanese PVTT Mastery: Precision Resection – Asian Boundary-Pushing Outcomes
Prof. Kiyoshi Hasegawa, MD, PhD
10:50–11:10
Chinese PVTT Conversion: Neoadjuvant to Hepatectomy – High-Volume East Wins
Prof. Shuqun Cheng, MD, PhD
11:10–11:30
IO in PVTT: STRIDE/HIMALAYA – Hong Kong East-West Lessons on Resistance & Candidacy
Prof. Stephen Lam Chan, MD, FRCP
11:30–11:50
Western & Australian View on PVTT: Palliative Systemic vs. Selective Aggressive Downstaging
Prof Shuichiro Shinna Japan & Western speaker (pref female eg Norrah Terrault??
Nutrition in Liver Disease
10:30–12:00 · Room 3
10:30–10:50
Talk 1 — topic TBC
TBC
10:50–11:10
Talk 2 — topic TBC
TBC
11:10–11:30
Talk 3 — topic TBC
TBC
11:30–11:50
Talk 4 — topic TBC
TBC
Nurse session 2 — Cirrhosis management
10:30–12:00 · Room 4
10:30–12:00
Individual talks to be confirmed
TBC
Management strategies in PSC– from 2027 to the future
10:30–12:00 · Room 5
10:30–10:55
State of the Art: Current and future management of PSC
Cynthia Levy (US)
10:55–11:00
Case presentation (?FMT ?Vanc)
Fellow
11:00–11:15
Diet and microbiome in PSC
Gerald Holtmann (QLD)
11:15–11:25
Cancer screening and chemoprevention in PSC
Kate Lynch (SA)
11:25–11:30
Patient lived experience (PSC)
Patient TBC
PUBLIC HEALTH Theme
10:30–12:00 · Room 6
10:30–10:45
MAFLD
Jeff Lazarus (Spain)
10:45–11:00
Global epidemic of MAFLD
Jeffrey Lazarus (Spain)
11:00–11:15
HCV MAFLD Pakistan pathways to care in low resource settings
Lubna Kamani (Pakistan)
11:15–11:30
ALD in Asia
Kenichi Ikejima (Japan)
11:30–11:45
HBV in Armenia
Hasmid Ghazian (Armenia)
HBV related morbidity and mortality
13:30–15:00 · Room 1
13:30–13:50
Individualizing HCC surveillance - best practice in 2027
Yoon Jung Kim (Sth Korea)
13:50–14:10
Redefining natural history and treatment guidelines in CHB
Young-Suk Lim (Sth Korea)
14:10–14:30
Utilising cohorts and big data to understand HBV better
Greg Dore (Aust)
14:30–14:50
Impact of vaccination on global hepatitis B morbidity and mortality- Lessons from Asia-Pacific
Lai Wei (China)
APASL Environmental Health and liver disease session
13:30–15:00 · Room 5
13:35–14:00
Plastic associated chemicals, including liver and GI inflammation and toxicity
Michaela Lucas (Australia)
14:00–14:15
Micronanoplastics: experts in this field.
Nicholas Chartres (AUSTRALIA)
14:15–14:30
exposome influence on the microbiome
Emad El-Omar (Australia)
14:30–14:45
impact of Climate Change on health, including liver and GI disease
Marina Romanello (UK)
The Next 15 Years of Hepatology: Emerging Leaders’ Perspectives
13:30–15:00 · Room 6
13:30–13:50
AI and Digital Technology in Hepatology
Jimmy Lai (HK)
13:50–14:10
How the Hepatology Patient Population Will Change
TBC
14:10–14:30
The Changing Skillset of the Hepatologist
SHANG-CHIN HUANG (Taiwan)
14:30–14:40
Young Investigator Presentation
TBC
FREE PAPERS 9 — Viral hepatitis
15:30–17:00 · Room 1
15:30–17:00
Individual free-paper abstracts / talks TBC
TBC
FREE PAPERS 10 — HCC / liver oncology
15:30–17:00 · Room 2
15:30–17:00
Individual free-paper abstracts / talks TBC
TBC
FREE PAPERS 11 — MAFLD / metabolic / ALD
15:30–17:00 · Room 3
15:30–17:00
Individual free-paper abstracts / talks TBC
TBC
FREE PAPERS 12 — Cirrhosis / PHT / transplant
15:30–17:00 · Room 4
15:30–17:00
Individual free-paper abstracts / talks TBC
TBC
Nurse session 3 — Viral hepatitis nurse-led models of care
15:30–17:00 · Room 6
15:30–17:00
Individual talks to be confirmed
TBC
Draft speaker program. Times and presentation details are subject to change.